350 related articles for article (PubMed ID: 28144129)
1. Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date.
Crotti C; Raimondo MG; Becciolini A; Biggioggero M; Favalli EG
Drug Des Devel Ther; 2017; 11():211-223. PubMed ID: 28144129
[TBL] [Abstract][Full Text] [Related]
2. Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis.
Crotti C; Biggioggero M; Becciolini A; Agape E; Favalli EG
Expert Opin Investig Drugs; 2019 Jul; 28(7):573-581. PubMed ID: 31208237
[No Abstract] [Full Text] [Related]
3. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
Burmester GR; McInnes IB; Kremer J; Miranda P; Korkosz M; Vencovsky J; Rubbert-Roth A; Mysler E; Sleeman MA; Godwood A; Sinibaldi D; Guo X; White WI; Wang B; Wu CY; Ryan PC; Close D; Weinblatt ME;
Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
[TBL] [Abstract][Full Text] [Related]
4. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
Guo X; Higgs BW; Bay-Jensen AC; Wu Y; Karsdal MA; Kuziora M; Godwood A; Close D; Ryan PC; Roskos LK; White WI
Rheumatology (Oxford); 2018 Jan; 57(1):175-184. PubMed ID: 29069507
[TBL] [Abstract][Full Text] [Related]
5. Mavrilimumab, a human monoclonal GM-CSF receptor-α antibody for the management of rheumatoid arthritis: a novel approach to therapy.
Nair JR; Edwards SW; Moots RJ
Expert Opin Biol Ther; 2012 Dec; 12(12):1661-8. PubMed ID: 23094973
[TBL] [Abstract][Full Text] [Related]
6. Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis.
Di Franco M; Gerardi MC; Lucchino B; Conti F
Core Evid; 2014; 9():41-8. PubMed ID: 24648832
[TBL] [Abstract][Full Text] [Related]
7. Targeting GM-CSF in rheumatoid arthritis.
Avci AB; Feist E; Burmester GR
Clin Exp Rheumatol; 2016; 34(4 Suppl 98):39-44. PubMed ID: 27586802
[TBL] [Abstract][Full Text] [Related]
8. Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects.
Crotti C; Agape E; Becciolini A; Biggioggero M; Favalli EG
Drugs; 2019 Nov; 79(16):1741-1755. PubMed ID: 31486005
[TBL] [Abstract][Full Text] [Related]
9. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.
Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R
Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321
[TBL] [Abstract][Full Text] [Related]
10. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study.
Burmester GR; Feist E; Sleeman MA; Wang B; White B; Magrini F
Ann Rheum Dis; 2011 Sep; 70(9):1542-9. PubMed ID: 21613310
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study.
Takeuchi T; Tanaka Y; Close D; Godwood A; Wu CY; Saurigny D
Mod Rheumatol; 2015 Jan; 25(1):21-30. PubMed ID: 24720551
[TBL] [Abstract][Full Text] [Related]
12. Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
Burmester GR; McInnes IB; Kremer JM; Miranda P; Vencovský J; Godwood A; Albulescu M; Michaels MA; Guo X; Close D; Weinblatt M
Arthritis Rheumatol; 2018 May; 70(5):679-689. PubMed ID: 29361199
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
Guo X; Wang S; Godwood A; Close D; Ryan PC; Roskos LK; White WI
Int J Rheum Dis; 2019 Apr; 22(4):646-653. PubMed ID: 30358109
[TBL] [Abstract][Full Text] [Related]
14. GM-CSF as a target in inflammatory/autoimmune disease: current evidence and future therapeutic potential.
Hamilton JA
Expert Rev Clin Immunol; 2015 Apr; 11(4):457-65. PubMed ID: 25748625
[TBL] [Abstract][Full Text] [Related]
15. Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab.
Cook AD; Hamilton JA
Ther Adv Musculoskelet Dis; 2018 Feb; 10(2):29-38. PubMed ID: 29387176
[TBL] [Abstract][Full Text] [Related]
16. Rheumatoid arthritis: new monoclonal antibodies.
Serio I; Tovoli F
Drugs Today (Barc); 2018 Mar; 54(3):219-230. PubMed ID: 29771256
[TBL] [Abstract][Full Text] [Related]
17. Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.
Greven DE; Cohen ES; Gerlag DM; Campbell J; Woods J; Davis N; van Nieuwenhuijze A; Lewis A; Heasmen S; McCourt M; Corkill D; Dodd A; Elvin J; Statache G; Wicks IP; Anderson IK; Nash A; Sleeman MA; Tak PP
Ann Rheum Dis; 2015 Oct; 74(10):1924-30. PubMed ID: 24936585
[TBL] [Abstract][Full Text] [Related]
18. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
19. GM-CSF as a therapeutic target in inflammatory diseases.
van Nieuwenhuijze A; Koenders M; Roeleveld D; Sleeman MA; van den Berg W; Wicks IP
Mol Immunol; 2013 Dec; 56(4):675-82. PubMed ID: 23933508
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary pharmacodynamics of an anti-GM-CSFRα antibody enables therapeutic dosing that limits exposure in the lung.
Campbell J; Nys J; Eghobamien L; Cohen ES; Robinson MJ; Sleeman MA
MAbs; 2016 Oct; 8(7):1398-1406. PubMed ID: 27560702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
